newsfilter
← Latest News
GlobeNewswire·

Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome

Globally renowned Alport syndrome experts will provide key insights Eloxx recently announced achievement of remission in one patient in its Phase 2 Alport syndrome clinical study and decision to advance into a pivotal